JP2014521625A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521625A5
JP2014521625A5 JP2014522075A JP2014522075A JP2014521625A5 JP 2014521625 A5 JP2014521625 A5 JP 2014521625A5 JP 2014522075 A JP2014522075 A JP 2014522075A JP 2014522075 A JP2014522075 A JP 2014522075A JP 2014521625 A5 JP2014521625 A5 JP 2014521625A5
Authority
JP
Japan
Prior art keywords
group
compound
alkyl
pharmaceutically acceptable
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014522075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521625A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/064598 external-priority patent/WO2013014185A1/en
Publication of JP2014521625A publication Critical patent/JP2014521625A/ja
Publication of JP2014521625A5 publication Critical patent/JP2014521625A5/ja
Ceased legal-status Critical Current

Links

JP2014522075A 2011-07-27 2012-07-25 二環式ピリミドン化合物 Ceased JP2014521625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/077702 2011-07-27
CN2011077702 2011-07-27
PCT/EP2012/064598 WO2013014185A1 (en) 2011-07-27 2012-07-25 Bicyclic pyrimidone compounds

Publications (2)

Publication Number Publication Date
JP2014521625A JP2014521625A (ja) 2014-08-28
JP2014521625A5 true JP2014521625A5 (OSRAM) 2015-08-20

Family

ID=46579034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014522075A Ceased JP2014521625A (ja) 2011-07-27 2012-07-25 二環式ピリミドン化合物

Country Status (12)

Country Link
US (2) US20130030012A1 (OSRAM)
EP (1) EP2736908A1 (OSRAM)
JP (1) JP2014521625A (OSRAM)
KR (1) KR20140059204A (OSRAM)
AR (1) AR087309A1 (OSRAM)
AU (1) AU2012288865B2 (OSRAM)
BR (1) BR112014001634A2 (OSRAM)
CA (1) CA2843102A1 (OSRAM)
RU (1) RU2014107486A (OSRAM)
TW (1) TW201321382A (OSRAM)
UY (1) UY34216A (OSRAM)
WO (1) WO2013014185A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130030012A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Compounds
EP2925730A1 (en) 2012-11-27 2015-10-07 Basf Se Substituted 2-[phenoxy-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds and their use as fungicides
WO2014082880A1 (en) 2012-11-27 2014-06-05 Basf Se Substituted [1,2,4] triazole compounds
WO2014082881A1 (en) 2012-11-27 2014-06-05 Basf Se Substituted 2-[phenoxy-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds and their use as fungicides
KR20150108896A (ko) * 2013-01-25 2015-09-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Lp-pla2의 억제제로서의 비시클릭 피리미돈 화합물
CN104968665A (zh) * 2013-01-25 2015-10-07 葛兰素史密斯克莱知识产权发展有限公司 作为lp-pla2抑制剂的双环嘧啶酮化合物
US9296755B2 (en) 2013-01-25 2016-03-29 Glaxosmithkline Intellectual Property Development Limited 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
CN106536525B (zh) 2014-07-22 2019-05-03 葛兰素史密斯克莱知识产权发展有限公司 化合物
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN105777653A (zh) * 2014-12-26 2016-07-20 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
WO2017040877A1 (en) * 2015-09-04 2017-03-09 Lysosomal Therapeutics Inc. Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
CN111868055B (zh) 2018-02-16 2024-03-08 勃林格殷格翰国际有限公司 Trpc6的抑制剂
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
CN112778331B (zh) 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
WO2021228159A1 (zh) * 2020-05-13 2021-11-18 上海纽思克生物科技有限公司 桥环嘧啶酮类化合物、其制备方法、其组合物和用途
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
AR002012A1 (es) 1994-12-22 1998-01-07 Smithkline Beecham Plc Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
KR19990028630A (ko) 1995-07-01 1999-04-15 데이비드 로버츠 아테롬성 동맥경화증을 치료하기 위한 아제티디논 유도체
CA2233300A1 (en) 1995-09-29 1997-04-10 Christopher Donald Southan A paf-acetylhydrolase and use in therapy
JP2000505063A (ja) 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン化合物
JP2000502079A (ja) 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
AU2698697A (en) 1996-04-26 1997-11-19 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
JP2001522844A (ja) 1997-11-06 2001-11-20 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ピリミジノン化合物およびそれを含有する医薬組成物
WO2000010980A1 (en) 1998-08-21 2000-03-02 Smithkline Beecham Plc Pyrimidinone derivatives for the treatment of atherosclerosis
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
PT1175408E (pt) 1999-05-01 2005-04-29 Smithkline Beecham Plc Derivados sulfonamida
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
BRPI0108396B1 (pt) 2000-02-16 2015-05-19 Smithkline Beecham Plc Derivados de pirimidina-4-ona como inibidores de ldl-pla2
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
EP2083625A4 (en) 2006-10-13 2011-10-19 Glaxo Group Ltd BICYCLIC HETOROAROMATIC COMPOUNDS
JP5437996B2 (ja) 2007-05-11 2014-03-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 皮膚潰瘍の治療方法
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
ES2456966T3 (es) * 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
US20130030012A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Compounds

Similar Documents

Publication Publication Date Title
JP2014521625A5 (OSRAM)
RU2014107486A (ru) Бициклические пиримидоновые соединения
JP2013537203A5 (OSRAM)
JP2013544860A5 (OSRAM)
JP2011519854A5 (OSRAM)
JP2013540755A5 (OSRAM)
JP2009263394A5 (OSRAM)
JP2013510120A5 (OSRAM)
PH12017501661A1 (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
CA2896976C (en) Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
JP2015510942A5 (OSRAM)
JP2014508811A5 (OSRAM)
JP2013542218A5 (OSRAM)
JP2016505058A5 (OSRAM)
JP2017533263A5 (OSRAM)
MA38323B1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
NZ627250A (en) Novel nicotinamide derivative or salt thereof
JP2017504635A5 (OSRAM)
JP2014511892A5 (OSRAM)
CA2864222A1 (en) Cycloalkane derivative
JP2014037426A5 (OSRAM)
JP2009533323A5 (OSRAM)
JP2016540803A5 (OSRAM)
JP2012502111A5 (OSRAM)
JP2014530838A5 (OSRAM)